Regen BioPharma (RGBP) seeks Rule 12b-25 extension for June 30, 2026 10-Q

Rhea-AI Filing Summary

Regen BioPharma, Inc. notified the SEC that it will file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 late. The company cites a delay in the review being performed by its public accountant that could not be overcome without unreasonable effort and expense. Relying on Rule 12b-25, Regen BioPharma states it expects to file the Form 10-Q no later than the fifth calendar day after the original due date. The company indicates that all other required periodic reports have been filed and that it does not anticipate any significant change in results of operations versus the same period last year.

Filing Explained

This filing is a late-filing notification, not the June 30, 2026 Form 10-Q itself; it does not contain the quarter’s interim financial statements, leaving that report pending as of August 13, 2026.

Key Figures

Reporting period end: June 30, 2026 Extension length for 10-Q: fifth calendar day Signature date: August 13, 2026 +1 more

4 metrics

Reporting period end June 30, 2026 Quarterly Report on Form 10-Q period covered

Extension length for 10-Q fifth calendar day Company expects to file Form 10-Q no later than this after due date

Signature date August 13, 2026 Date the Chief Executive Officer signed the notification

CEO contact phone (619) 227-9192 Telephone number provided for inquiries about the notification

Key Terms

Rule 12b-25, Form 10-Q, significant change in results of operations

3 terms

Rule 12b-25 regulatory

"In accordance with Rule 12b-25 of the Securities Exchange Act of 1934"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q financial

"its Quarterly Report on Form 10-Q for the period ended June 30, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

significant change in results of operations financial

"Is it anticipated that any significant change in results of operations"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 01:51 PM Accepted by SEC EDGAR 08/13/2026 - 01:51 PM Learn about SEC filing dates

FAQ

Why did Regen BioPharma (RGBP) file a Form 12b-25 for its June 30, 2026 10-Q?

Regen BioPharma filed Form 12b-25 because its public accountant’s review caused a delay in completing the June 30, 2026 Form 10-Q. The company states this delay could not be resolved without unreasonable effort and expense, so it requested the permitted extension.

When does Regen BioPharma (RGBP) expect to file the delayed June 30, 2026 Form 10-Q?

Regen BioPharma expects to file the Form 10-Q no later than the fifth calendar day after the prescribed due date. This timing is consistent with the extension allowed for quarterly reports under Rule 12b-25 of the Securities Exchange Act of 1934.

Does Regen BioPharma (RGBP) expect significant changes in results in the delayed 10-Q?

Regen BioPharma indicates it does not anticipate any significant change in results of operations versus the corresponding period of the prior year. The company therefore did not attach any narrative or quantitative explanation of major earnings changes to this notification.

Have all other required SEC reports been filed by Regen BioPharma (RGBP)?

Regen BioPharma states that all other required periodic reports under Sections 13 or 15(d) have been filed for the preceding 12 months or required period. This late-filing notification applies only to the June 30, 2026 Form 10-Q.

What SEC rule is Regen BioPharma (RGBP) relying on for its late Form 10-Q?

Regen BioPharma is relying on Rule 12b-25, which allows extra time to file periodic reports. Under this rule, the company plans to submit its June 30, 2026 Form 10-Q within five calendar days of the original due date for quarterly reports.

Who signed the Regen BioPharma (RGBP) late-filing notification for the June 30, 2026 10-Q?

The notification was signed by David Koos, Chief Executive Officer of Regen BioPharma, Inc., on August 13, 2026. He is listed as the authorized officer and primary contact, with a telephone number provided for further inquiries.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

SEC File Number 333-191725

NOTIFICATION OF LATE FILING

(Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

For Period Ended: June 30, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR

For the Transition Period Ended: ________________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Regen BioPharma, Inc.

Full Name of Registrant

Former Name of Registrant

8697 La Mesa Blvd, Ste C #107

Address of Principal Executive Officer (Street and Number)

La Mesa, CA 91941

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III— NARRATIVE

State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The Company could not complete the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2026 due to a delay related to the review being performed by the Company’s public accountant which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-Q no later than the fifth calendar day following the prescribed due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

David Koos		(619)		227-9192
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Regen BioPharma, Inc.

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 13, 2026	By:	/s/ David Koos
		David Koos
		Chief Executive Officer